Product Name: Basic Cytokeratin Antibody [SPM591]
Species Reactivity: Human, Mouse, Rat
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 0.5-1 ug/mlWestern blot: 0.5-1 ug/mlImmunohistochemistry (FFPE): 0.25-0.5 ug/ml for 30 min at RT (1)Prediluted format: incubate for 30 min at RT (2)Optimal dilution of the Basic Cytokeratin antibody should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Solubilized keratin extract from human stratum corneum was used as the immunogen for the Basic Cytokeratin antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 978-62-1
Product: IMD-0354
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: KRT2B, KRT2P, Keratin, type II cytoskeletal 2 oral, Cytokeratin-2P, CK-2P, HUMCYT2A
Accession NO.:
Protein Ino:
Official Symbol: KRT76
Geneid: 51350
Background: This antibody recognizes CK1, CK5, CK10 and CK14. In normal epithelia, it stains stratified epithelia, myoepithelial cells and basal cells in the prostate gland and bronchi. This mAb shows no reactivity with hepatocytes, pancreatic acinar cells, proximal renal tubules, or endometrial glands; there is no reactivity with cells derived from simple epithelia. Mesenchymal tumors, lymphomas, melanomas, neural tumors, and neuroendocrine tumors are negative with this antibody. It stains myoepithelial cells and has been shown to be useful in distinguishing prostate adenocarcinoma from benign prostate. This antibody has also been useful in separating benign from malignant intraductal breast proliferations.
PubMed ID:http://aac.asm.org/content/53/10/4200.abstract
